Seyed Alireza Rabi, M.D.,Ph.D.
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
Name | Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
---|
HIV-1 | 16 | 2017 | 6966 | 0.610 |
Why?
|
Virus Internalization | 4 | 2022 | 501 | 0.480 |
Why?
|
CD4-Positive T-Lymphocytes | 11 | 2017 | 4419 | 0.450 |
Why?
|
HIV Protease | 1 | 2013 | 98 | 0.430 |
Why?
|
HIV Long-Term Survivors | 2 | 2011 | 140 | 0.430 |
Why?
|
HIV Protease Inhibitors | 3 | 2013 | 432 | 0.400 |
Why?
|
Virus Replication | 8 | 2017 | 2459 | 0.390 |
Why?
|
Drug Resistance, Viral | 2 | 2013 | 869 | 0.370 |
Why?
|
Virus Latency | 6 | 2017 | 360 | 0.280 |
Why?
|
Antiretroviral Therapy, Highly Active | 6 | 2012 | 1903 | 0.260 |
Why?
|
env Gene Products, Human Immunodeficiency Virus | 2 | 2013 | 381 | 0.180 |
Why?
|
Organ Preservation | 1 | 2024 | 389 | 0.180 |
Why?
|
Heart Transplantation | 2 | 2023 | 3291 | 0.160 |
Why?
|
Anti-HIV Agents | 5 | 2013 | 4567 | 0.150 |
Why?
|
HIV Infections | 11 | 2013 | 17564 | 0.150 |
Why?
|
RNA, Viral | 3 | 2022 | 2865 | 0.140 |
Why?
|
Simian Acquired Immunodeficiency Syndrome | 2 | 2010 | 545 | 0.120 |
Why?
|
Tissue and Organ Procurement | 1 | 2023 | 983 | 0.120 |
Why?
|
HIV | 2 | 2012 | 1596 | 0.120 |
Why?
|
Lung Transplantation | 1 | 2024 | 1310 | 0.120 |
Why?
|
Cardiac Glycosides | 1 | 2013 | 29 | 0.110 |
Why?
|
Anti-Retroviral Agents | 3 | 2012 | 1794 | 0.110 |
Why?
|
Virus Release | 1 | 2013 | 35 | 0.110 |
Why?
|
Virus Attachment | 1 | 2013 | 57 | 0.110 |
Why?
|
Proviruses | 2 | 2012 | 320 | 0.110 |
Why?
|
Immunologic Memory | 2 | 2017 | 1375 | 0.100 |
Why?
|
Reverse Transcriptase Polymerase Chain Reaction | 3 | 2017 | 4586 | 0.100 |
Why?
|
Virion | 2 | 2011 | 430 | 0.100 |
Why?
|
Virus Activation | 1 | 2013 | 322 | 0.100 |
Why?
|
Transcription, Genetic | 2 | 2017 | 7599 | 0.090 |
Why?
|
DNA, Viral | 3 | 2012 | 2206 | 0.090 |
Why?
|
T-Lymphocytes, Cytotoxic | 2 | 2017 | 1797 | 0.080 |
Why?
|
Viral Load | 3 | 2013 | 3399 | 0.080 |
Why?
|
Fluorescence Resonance Energy Transfer | 1 | 2010 | 420 | 0.080 |
Why?
|
Oligopeptides | 1 | 2013 | 1193 | 0.070 |
Why?
|
Simian immunodeficiency virus | 2 | 2010 | 814 | 0.070 |
Why?
|
Genes, Reporter | 1 | 2010 | 1525 | 0.070 |
Why?
|
Biological Evolution | 1 | 2012 | 1081 | 0.070 |
Why?
|
Staining and Labeling | 1 | 2010 | 1083 | 0.070 |
Why?
|
Tissue Donors | 3 | 2023 | 2377 | 0.070 |
Why?
|
Dose-Response Relationship, Drug | 3 | 2013 | 10784 | 0.070 |
Why?
|
Central Nervous System Diseases | 1 | 2010 | 521 | 0.060 |
Why?
|
Drug Combinations | 1 | 2012 | 2079 | 0.060 |
Why?
|
Models, Biological | 2 | 2012 | 9505 | 0.060 |
Why?
|
Drug Therapy, Combination | 2 | 2012 | 6320 | 0.060 |
Why?
|
Green Fluorescent Proteins | 1 | 2010 | 2072 | 0.060 |
Why?
|
Acquired Immunodeficiency Syndrome | 1 | 2013 | 2203 | 0.060 |
Why?
|
Bone Marrow Cells | 1 | 2012 | 2415 | 0.060 |
Why?
|
Mutation, Missense | 1 | 2013 | 2594 | 0.060 |
Why?
|
HEK293 Cells | 1 | 2013 | 4294 | 0.060 |
Why?
|
Cold Ischemia | 1 | 2024 | 73 | 0.050 |
Why?
|
Sulfonamides | 1 | 2013 | 1988 | 0.050 |
Why?
|
Cells, Cultured | 3 | 2017 | 19041 | 0.050 |
Why?
|
Monocytes | 1 | 2011 | 2591 | 0.050 |
Why?
|
Pyridines | 1 | 2013 | 2888 | 0.050 |
Why?
|
Guanidines | 1 | 2022 | 194 | 0.050 |
Why?
|
Esters | 1 | 2022 | 212 | 0.050 |
Why?
|
Brain Death | 1 | 2023 | 360 | 0.040 |
Why?
|
Hematopoietic Stem Cells | 1 | 2012 | 3408 | 0.040 |
Why?
|
Death | 1 | 2023 | 683 | 0.040 |
Why?
|
Lymphocyte Activation | 3 | 2017 | 5495 | 0.040 |
Why?
|
Protease Inhibitors | 1 | 2022 | 753 | 0.040 |
Why?
|
Heart Failure | 1 | 2023 | 11857 | 0.040 |
Why?
|
Humans | 22 | 2024 | 768451 | 0.040 |
Why?
|
Gastrointestinal Tract | 1 | 2022 | 840 | 0.030 |
Why?
|
Macrophages | 1 | 2011 | 5797 | 0.030 |
Why?
|
Feces | 1 | 2022 | 1515 | 0.030 |
Why?
|
Disease Progression | 1 | 2011 | 13655 | 0.030 |
Why?
|
Receptors, HIV | 1 | 2013 | 159 | 0.030 |
Why?
|
Feasibility Studies | 1 | 2024 | 5308 | 0.030 |
Why?
|
Graft Survival | 1 | 2023 | 3890 | 0.030 |
Why?
|
Cytopathogenic Effect, Viral | 1 | 2012 | 152 | 0.030 |
Why?
|
Integrase Inhibitors | 1 | 2011 | 12 | 0.020 |
Why?
|
Time Factors | 2 | 2024 | 40271 | 0.020 |
Why?
|
Drug Repositioning | 1 | 2013 | 244 | 0.020 |
Why?
|
Receptors, CCR5 | 1 | 2013 | 490 | 0.020 |
Why?
|
Genetic Fitness | 1 | 2012 | 120 | 0.020 |
Why?
|
Protein Interaction Domains and Motifs | 1 | 2013 | 452 | 0.020 |
Why?
|
Inflammation | 1 | 2010 | 10865 | 0.020 |
Why?
|
Antigens, CD34 | 1 | 2012 | 656 | 0.020 |
Why?
|
Antiviral Agents | 1 | 2022 | 3063 | 0.020 |
Why?
|
Cytokines | 2 | 2017 | 7449 | 0.020 |
Why?
|
Virus Integration | 1 | 2011 | 306 | 0.020 |
Why?
|
Host-Pathogen Interactions | 1 | 2017 | 1465 | 0.020 |
Why?
|
Inhibitory Concentration 50 | 1 | 2009 | 467 | 0.020 |
Why?
|
Receptors, CXCR4 | 1 | 2013 | 729 | 0.020 |
Why?
|
Gene Expression Regulation, Viral | 1 | 2011 | 435 | 0.020 |
Why?
|
DNA Primers | 1 | 2013 | 2826 | 0.020 |
Why?
|
Gene Expression Profiling | 2 | 2017 | 9507 | 0.020 |
Why?
|
Cytotoxicity, Immunologic | 1 | 2012 | 1355 | 0.020 |
Why?
|
Reverse Transcriptase Inhibitors | 1 | 2011 | 622 | 0.020 |
Why?
|
Species Specificity | 1 | 2012 | 2422 | 0.020 |
Why?
|
Coculture Techniques | 1 | 2012 | 1343 | 0.020 |
Why?
|
High-Throughput Screening Assays | 1 | 2013 | 940 | 0.020 |
Why?
|
Macaca | 1 | 2009 | 417 | 0.020 |
Why?
|
Lymphocyte Count | 1 | 2009 | 793 | 0.020 |
Why?
|
Flow Cytometry | 1 | 2017 | 5904 | 0.020 |
Why?
|
Viremia | 1 | 2009 | 725 | 0.020 |
Why?
|
Cell Death | 1 | 2011 | 1684 | 0.020 |
Why?
|
Rats | 1 | 2022 | 23839 | 0.020 |
Why?
|
Adaptive Immunity | 1 | 2010 | 736 | 0.020 |
Why?
|
Epitopes | 1 | 2011 | 2526 | 0.020 |
Why?
|
Retrospective Studies | 2 | 2024 | 81834 | 0.010 |
Why?
|
HIV Antibodies | 1 | 2011 | 1341 | 0.010 |
Why?
|
Disease Susceptibility | 1 | 2011 | 1797 | 0.010 |
Why?
|
Phylogeny | 1 | 2011 | 2846 | 0.010 |
Why?
|
Macaca mulatta | 1 | 2010 | 2363 | 0.010 |
Why?
|
Lung | 1 | 2022 | 10090 | 0.010 |
Why?
|
Adult | 3 | 2024 | 223542 | 0.010 |
Why?
|
Antibodies, Neutralizing | 1 | 2011 | 2008 | 0.010 |
Why?
|
Bone Marrow | 1 | 2012 | 2929 | 0.010 |
Why?
|
Male | 5 | 2024 | 364781 | 0.010 |
Why?
|
Protein Binding | 1 | 2013 | 9376 | 0.010 |
Why?
|
Risk Assessment | 1 | 2023 | 24311 | 0.010 |
Why?
|
Medication Adherence | 1 | 2012 | 2190 | 0.010 |
Why?
|
Amino Acid Sequence | 1 | 2011 | 13452 | 0.010 |
Why?
|
Cell Line | 1 | 2013 | 15609 | 0.010 |
Why?
|
Cohort Studies | 2 | 2013 | 41797 | 0.010 |
Why?
|
Molecular Sequence Data | 1 | 2011 | 17647 | 0.010 |
Why?
|
Computer Simulation | 1 | 2012 | 6278 | 0.010 |
Why?
|
Animals | 3 | 2022 | 169418 | 0.010 |
Why?
|
Middle Aged | 3 | 2024 | 223418 | 0.010 |
Why?
|
Immunity, Innate | 1 | 2010 | 3080 | 0.010 |
Why?
|
CD8-Positive T-Lymphocytes | 1 | 2011 | 4642 | 0.010 |
Why?
|
Lymph Nodes | 1 | 2009 | 3472 | 0.010 |
Why?
|
Chronic Disease | 1 | 2011 | 9382 | 0.010 |
Why?
|
Aged | 2 | 2024 | 171520 | 0.010 |
Why?
|
Female | 3 | 2024 | 396943 | 0.010 |
Why?
|
Phenotype | 1 | 2011 | 16712 | 0.010 |
Why?
|
Reproducibility of Results | 1 | 2011 | 20231 | 0.010 |
Why?
|
Algorithms | 1 | 2012 | 14158 | 0.010 |
Why?
|
Disease Models, Animal | 1 | 2009 | 18388 | 0.010 |
Why?
|
Mutation | 1 | 2012 | 30243 | 0.000 |
Why?
|
Treatment Outcome | 1 | 2012 | 65409 | 0.000 |
Why?
|